The first purpose of this study is to test the safety of the addition of a new drug called inotuzumab along with the usual chemotherapy drugs used for adolescent young adults. Inotuzumab is investigational and is not FDA-approved. There will be about 6 to 12 patients taking part in this first portion of the study.
The second purpose of this study is to compare any good and bad effects of using inotuzumab along with the usual chemotherapy treatment for ALL cancer to using the usual treatment alone. The addition of inotuzumab to the usual treatment could prevent the cancer from returning or getting worse but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. There will be about 324 people taking part in this study.